With two observations under Form 483
Biocon announced that the USFDA conducted a post-approval and GMP inspection of the company's small molecule API manufacturing facility at 20th KM, Biocon Campus, Bengaluru between 20 February 2020 and 26 February 2020.At the conclusion of the inspection, the agency issued a Form 483 with two observations which are procedural in nature.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
